(Reuters) - Eli Lilly and Co's stomach cancer drug ramucirumab met its primary goal of improving overall survival in a late stage-study, extending the lives of patients for more than a month longer than those who received a placebo, the American Society of Clinical Oncology said on Tuesday. The overall survival among patients treated with the Lilly drug in the study was 5.2 months, compared with 3.8 months for those who received a placebo. However, some analysts were looking for a survival benefit greater than two months from the monoclonal antibody. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment